Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer

Inclusion Criteria: * Patient with non-resectable metastatic colorectal cancer * Metastatic disease not amenable to surgical resection * Patient in second line treatment after progression according to RECIST criteria * Patient with measurable lesions according to RECIST criteria (version 1.1) * Patient eligible for a standard second line treatment with FOLFIRI * Patient with ECOG ≤ 2 * Patient with adequate organ function * Patient with life expectancy \> 3 months * Female or male patient ≥ 18 * Patient weight \> 40 kg and BMI \> 18 Exclusion Criteria: * Patient who cannot receive FOLFIRI * More than 1 prior chemotherapy regimens for metastatic colorectal cancer * Pregnant, intent to be pregnant, or nursing female patient * Patient with any chronic inflammatory bowel disease * Patient treated for a cancer other than colorectal cancer within five years before enrollment * Patient with an hepatic involvement \> 50% * Patient with active central nervous system (CNS) metastasis or history of CNS metastases * Patient with an active infection * Patient presenting with cardiac disorders * Any previous treatment with an investigational agent or chemotherapy or biological agent within four weeks prior to baseline.